atosiban
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
124
Go to page
1
2
3
4
5
February 07, 2026
An individual participant data network meta-analysis of the APOSTEL trials on the effect of tocolysis in threatened preterm birth between 30-33+6 weeks of gestation in twin pregnancies.
(PubMed, Eur J Obstet Gynecol Reprod Biol)
- "No clear benefit of nifedipine or atosiban over placebo on neonatal outcomes in twin pregnancies with threatened preterm birth between 30+0 and 33+6 weeks was found."
Journal • Retrospective data
January 17, 2026
Molecular basis of antagonism of the dimeric human arginine vasopressin receptor 1A.
(PubMed, Nat Commun)
- "Here, we present structures of human V1aR in its apo state and in complexes with antagonists: atosiban, balovaptan, and SRX246. Antagonist-bound structures, combined with mutagenesis and radioligand binding assays, uncover distinct binding modes and key determinants for antagonism and selectivity. These findings provide a comprehensive understanding of V1aR assembly and dynamic regulation, offering valuable insights for structure-guided development of new antagonists targeting dimeric V1aR for CNS disorders."
Journal • CNS Disorders
December 02, 2025
Effects of oxytocin receptor antagonization in migraine: A randomized, double-blind, placebocontrolled human provocation study
(EHF-EHC 2025)
- "Short-lasting oxytocin inhibition through the OT-receptor antagonist atosiban did not significantly increase the incidence of migraine attacks in women with episodic migraine, although a numerical trend was observed."
Clinical • CNS Disorders • Migraine • Pain
December 21, 2025
Atosiban-conjugated 3WJ-pRNA nanoparticles delivering GAS1-enhanced extracellular vesicles: targeting the decidua to combat recurrent miscarriage.
(PubMed, J Nanobiotechnology)
- "This study unveils that the GAS1-RAB39B axis may play a significant role in EV-mediated decidual communication and provide a potential non-invasive, RNA nanotechnology-driven strategy for RM treatment."
Journal • Immunology • GAS1
December 25, 2025
Atosiban as a potential treatment for endometriosis-related pain: results from the ENDOBAN pilot study.
(PubMed, Fertil Steril)
- No abstract available
Journal • Endometriosis • Gynecology • Pain • Women's Health
December 10, 2025
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
(clinicaltrials.gov)
- P=N/A | N=792 | Recruiting | Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi | Not yet recruiting ➔ Recruiting
Enrollment open • Infertility • Sexual Disorders
December 02, 2025
Abnormal Endometrial Peristalsis in Frozen-Thawed Embryo Transfer: Risk Factors and Improvements of Atosiban Treatment.
(PubMed, Reprod Fertil)
- "The benefit was even greater when embryos were transferred at an early stage (Day 3 embryos). This suggests that detecting and treating abnormal uterine movements could improve the chances of pregnancy for some women undergoing IVF, especially those receiving early-stage embryos."
Journal • Infertility
November 15, 2025
Effects of oxytocin receptor ligands on anxiogenic-like effect, social avoidance and changes on medial prefrontal cortex oxytocin receptor expression evoked by chronic social defeat stress in rats.
(PubMed, Prog Neurobiol)
- "We investigated the effect of systemic administration of the synthetic oxytocin (OXT) analog carbetocin and/or OXT receptor antagonists (atosiban and L-368,899) on social avoidance and anxiogenic-like effect in male rats subjected to chronic social defeat stress (cSDS). Taken together, our study provides evidence for the critical role of the OXT system and its pharmacological manipulation in modulating anxiogenic-like effects evoked by social stress. Furthermore, the region-specific modulation of OXT receptor expression within the mPFC by stress and OXT system pharmacological manipulation emphasize the complex and dynamic nature of OXT receptor regulation in brain regions crucial for emotional processing."
Journal • Preclinical • Mood Disorders • Psychiatry
November 01, 2025
Safety and efficacy of atosiban for fetomaternal resuscitation following severe placental abruption in preparation for an emergency caesarean section: a narrative review.
(PubMed, Expert Opin Drug Saf)
- "The contribution of maternal uterine hypertonus/tachysystole and increased uterine tone/pressure that affects fetal hypoxia/acidosis and consumption coagulopathy, strengthens the case for the use of a tocolytic to relax the uterus and improve fetal oxygenation. Due to its safety and efficacy profile, we make the case for atosiban as an agent to reduce uterine contractile frequency, tone and pressure to improve fetal oxygenation and improve fetomaternal outcome."
Journal • Review • Hematological Disorders • Metabolic Disorders
October 29, 2025
Advancing Sustainable Synthesis of Cyclic Peptides by Integrating Aqueous Fmoc/t-Bu Solid-Phase Peptide Synthesis with Disulfide Bond Formation and TFA/PFAS-Free Resin Cleavage.
(PubMed, J Org Chem)
- "Lett. 2024, 26, 6787-6791], we now report that ASPPS can be integrated with disulfide formation and TFA/PFA-free cleavage toward a new platform for sustainable synthesis of cyclic peptides, illustrated by synthesizing labor suppressant atosiban by both on-resin cyclization/cleavage and cleavage/solution cyclization approaches."
Journal
October 11, 2025
Tocolysis for preterm labor with intact membranes
(PubMed, Gynecol Obstet Fertil Senol)
- "Nifedpine and atosiban are recommanded as first line tocolysis since the clinical guidelines published in 2016 by the French College of Obstetrics and Gynecology (CNGOF)...Beyond medication, other parameters need to be considered such as national and territorial health organization, specific to each country. A collegial opinion with a revision of the national guidelines including all the parameters is necessary before any change in preterm labor management."
Journal • Gynecology • Obstetrics
September 28, 2025
Atosiban for threatened preterm birth: the APOSTEL 8 trial.
(PubMed, Lancet)
- No abstract available
Journal
September 28, 2025
Atosiban for threatened preterm birth: the APOSTEL 8 trial.
(PubMed, Lancet)
- No abstract available
Journal
September 28, 2025
Atosiban for threatened preterm birth: the APOSTEL 8 trial - Authors' reply.
(PubMed, Lancet)
- No abstract available
Journal
September 27, 2025
Investigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats.
(PubMed, Biomedicines)
- " These findings indicate that oxytocin contributes to bladder and prostate hypercontractility, particularly in obesity. Targeting OXTR with atosiban may represent a novel therapeutic strategy for the management of LUTS, OAB, and BPH."
Journal • Preclinical • Benign Prostatic Hyperplasia • Genetic Disorders • Obesity • Overactive Bladder • Urinary Incontinence
September 26, 2025
On-Resin Synthesis and Late-Stage Functionalization of Macrocyclic Atosiban Mimetics via 5-Iodo-1,4-triazoles.
(PubMed, Org Lett)
- "Structural analysis revealed that the 5-iodo substituent influences the peptide conformation. These findings establish 5-iodo-1,4-triazoles as versatile, tunable motifs for macrocyclization and functionalization, expanding the chemical space accessible to macrocyclic peptide chemical biology tools and therapeutics."
Journal
September 25, 2025
Comparative analysis of magnesium sulfate and atosiban in fetal neuroprotection during high-risk pregnancies.
(PubMed, Pak J Pharm Sci)
- "It is also observed that considering maternal safety, it has fewer side effects. Future larger population studies should be carried out to corroborate the results for higher efficient and safer intervention for fetal neuroprotection."
Clinical • Journal • Cardiovascular • Cerebral Palsy • CNS Disorders • Critical care • Developmental Disorders • Hypertension • Respiratory Diseases
September 23, 2025
Atosiban in Single Blastocyst Transfer in Patients With Previous Pregnancy Failure and Abnormal Uterine Contractions
(clinicaltrials.gov)
- P=N/A | N=792 | Not yet recruiting | Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi
New trial • Infertility • Sexual Disorders
September 10, 2025
A neural circuit from hypothalamic paraventricular oxytocin neurons to trigeminal nucleus caudalis GABAergic neurons modulates pain sensitization in a mouse model of chronic migraine.
(PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
- "PVN OXT neurons exert a descending facilitatory effect on GABAergic neurons in the TNC via OXT release, thereby ameliorating pain sensitization in chronic migraine."
Journal • Preclinical • CNS Disorders • Migraine • Pain • FOS • OXT
August 26, 2025
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
(clinicaltrials.gov)
- P1 | N=250 | Recruiting | Sponsor: University of Electronic Science and Technology of China
New P1 trial
August 28, 2025
Dual Oxytocin Signals in Striatal Astrocytes.
(PubMed, Biomolecules)
- "Our main findings are as follows: oxytocin could induce dual responses in astrocyte processes, namely the inhibition and facilitation of both Ca2+ signals and glutamate release; the inhibitory and the facilitatory response appeared dependent on activation of the Gi and the Gq pathway, respectively; both inhibitory and facilitatory responses were evoked at the same nanomolar oxytocin concentrations; and the biased agonists atosiban and carbetocin could duplicate oxytocin's inhibitory and facilitatory response, respectively. In conclusion, due to the coupling of striatal astrocytic oxytocin receptors to different transduction pathways and the dual effects on Ca2+ signals and glutamate release, oxytocin could also play a crucial role in neuron-astrocyte bi-directional communication through a subtle regulation of striatal glutamatergic synapses. Therefore, astrocytic oxytocin receptors may offer pharmacological targets to regulate glutamatergic striatal transmission,..."
Journal • CNS Disorders • Mental Retardation • Psychiatry
July 31, 2025
OTAtosiban: The Effect of Oral Oxytocin and Atosiban on Social Attention
(clinicaltrials.gov)
- P1 | N=250 | Recruiting | Sponsor: University of Electronic Science and Technology of China
New P1 trial
August 10, 2025
Efficacy and safety of ebopiprant to delay preterm birth after oral administration in pregnant women with spontaneous preterm labor receiving atosiban: a phase 2a, double-blind, parallel group, randomized, placebo-controlled, proof of concept study.
(PubMed, Eur J Obstet Gynecol Reprod Biol)
- P2a | "Ebopiprant added to atosiban infusion may reduce the probability of delivering within 48 h."
Journal • P2a data • IGFBP1
August 14, 2025
Intrathecal injections of non-peptide oxytocin receptor agonists, WAY 267,464 and TC OT 39, induce significant anti-hyperalgesia in both male and female rats with inflammatory pain.
(PubMed, Iran J Basic Med Sci)
- "Atosiban, an OTR antagonist, was also co-administered with these compounds to confirm their involvement in OTR activation...These compounds induced significant anti-hyperalgesia without any sex differences, suggesting that the inhibition of IRAP degradation eliminated the variation in oxytocin's effects based on sex. Therefore, we propose these compounds as promising candidates for treating inflammatory hyperalgesia in clinical applications."
Journal • Preclinical • Pain
July 31, 2025
Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis.
(PubMed, Cancer Res)
- "ChIP assays showed that YAP bound to the enhancer region of OXTR and facilitated its transcription, creating a positive feedback loop. Together, this study uncovered the interplay between Hippo signaling and the OXTR pathway in hepatocarcinogenesis and established OXTR inhibition with atosiban as a promising strategy for treating HCC."
Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor
1 to 25
Of
124
Go to page
1
2
3
4
5